




PHARMACEUTICAL 2023

InMed Pharmaceuticals Inc.
Rank 334 of 446





PHARMACEUTICAL 2023

InMed Pharmaceuticals Inc.
Rank 334 of 446

The relative strengths and weaknesses of InMed Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of InMed Pharmaceuticals Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 27% points. The greatest weakness of InMed Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 124% points.

The company's Economic Capital Ratio, given in the ranking table, is -36%, being 79% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	9,598
Cost of Goods Sold	546
Intangible Assets	2,109
Liabilities, Current	3,320
Liabilities, Non-Current	389
Other Assets	1,081
Other Compr. Net Income	0
Other Expenses	4,973
Other Liabilities	0
Other Net Income	-21
Other Revenues	1,089
Property and Equipment	0
Research and Development	7,283
Selling, General and Administrative Expense	6,867

Output Variable	Value in 1000 USD
Assets	12,788
Liabilities	3,709
Expenses	19,668
Revenues	1,089
Stockholders Equity	9,079
Net Income	-18,600
Comprehensive Net Income	-18,600
Economic Capital Ratio	-36%